CAJ | 학술논문

目的观察联合依折麦布对单独应用他汀类药物未能使低密度脂蛋白胆固醇(LDL-C)达标的冠心病合并糖尿病患者血脂的影响.方法 61例应用他汀治疗12周后LDL-C未达标(<2.07mmol/L)的冠心病合并糖尿病患者,在原用药基础上联合应用依折麦布(10mg/d),观察治疗8周后的血脂水平,及对丙氨酸氨基转氨酶(ALT)、天门冬氨酸氨基转氨酶(AST)及肌酸激酶(CK)的影响.结果干预前LDL-C未达标的61例患者LDL-C分别为(2.74±0.43)nmaol/L和(2.19±0.32)mmol/L(P=0.03);干预后LDL-C水平下降20.1%(P<0.05),总胆固醇(TC)下降19.1%(P<0.05),LDL-C水平达标率为74%(45/61).干预前后甘油三酯(TG)和高密度脂蛋白胆固醇(HDL-C)无显著变化(P>0.05),AST、ALT和CK等指标也无显著变化(P>0.05).结论联合应用依折麦布可以提高他汀类药物治疗冠心病合并糖尿病患者的LDL-C达标率,使LDL-C水平进一步降低.
목적 관찰연합의절맥포대단독응용타정류약물미능사저밀도지단백담고순(LDL-C)체표적관심병합병당뇨병환자혈지적영향.방법 61례응용타정치료12주후LDL-C미체표(<2.07mmol/L)적관심병합병당뇨병환자,재원용약기출상연합응용의절맥포(10mg/d),관찰치료8주후적혈지수평,급대병안산안기전안매(ALT)、천문동안산안기전안매(AST)급기산격매(CK)적영향.결과 간예전LDL-C미체표적61례환자LDL-C분별위(2.74±0.43)nmaol/L화(2.19±0.32)mmol/L(P=0.03);간예후LDL-C수평하강20.1%(P<0.05),총담고순(TC)하강19.1%(P<0.05),LDL-C수평체표솔위74%(45/61).간예전후감유삼지(TG)화고밀도지단백담고순(HDL-C)무현저변화(P>0.05),AST、ALT화CK등지표야무현저변화(P>0.05).결론 연합응용의절맥포가이제고타정류약물치료관심병합병당뇨병환자적LDL-C체표솔,사LDL-C수평진일보강저.
Objective To investigate the efficacy and safety of ezctimibe on uncontrolled LDL-C when added to ongoing statin therapy in patients with coronary heart diseases (CHD) and diabetes mellitus (DM). Methods 61 patients with LDL-C level exceeding target goal (<2.07 mmol/L) after 12 weeks' treatment with statins, received ezetimibe in addition to their ongoing statin therapy for 8 weeks. Lipid parameters, alanine aminotransferase(ALT), aspartic aminotransferase(AST) and ereatine kinase(CK) were compared before and after the adding of ezetimibe. Results LDL-C before and after the adding of ezetimibe was (2.74±0.43) mmol/L and (2.19±0.32) mmol/L, respectively (P=0.03) in 61 patients. Ezetimibe added to statin therapy significantly reduced the LDL-C level and TC level by additional 20.1% and 19.1%, respectively (P<0.05). 74%(45/61) patients treated with ezetimibe added to statin reached their target LDL-C goal. No change of TG and HDL-C was observed and no change of AST, ALT and CK was found either. Conclusion Ezetimibe added to statin therapy lowered LDL-C level further and improved the goal attainment in patients with CHD and DM.